Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: A 19-week, phase ii, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease

Clinical Therapeutics

Volumn 29, Issue 4, 2007, Pages 626-639

  Besarab, Anatole ^a   Salifu, Moro O ^b   Lunde, N Martin ^c   Bansal, Vinod ^d   Fishbane, Steven ^e   Dougherty, Frank C ^f   Beyer, Ulrich ^f  

^a HENRY FORD HOSPITAL   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c Twin Cities Clinical Research   (United States)

^d LOYOLA UNIVERSITY CHICAGO   (United States)

^e WINTHROP UNIVERSITY HOSPITAL   (United States)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

anemia; C.E.R.A.; continuous erythropoietin receptor activator; hemoglobin

Indexed keywords

CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR; ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ADULT; ANEMIA; ARTICLE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS; DIARRHEA; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FEVER; HEADACHE; HEMOGLOBIN DETERMINATION; HUMAN; MALE; MALIGNANT HYPERTENSION; MULTICENTER STUDY; MUSCLE CRAMP; MUSCLE SPASM; NAUSEA; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ANALYSIS OF VARIANCE; ANEMIA; DRUG ADMINISTRATION SCHEDULE; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; REGRESSION ANALYSIS; RENAL DIALYSIS;

EID: 34347390681     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.04.014     Document Type: Article

References (45)

1. Astor B.C., Muntner P., Levin A., et al. Association of kidney function with anemia: The Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med. 162 (2002) 1401-1408
2. Hörl W.H., Macdougall I.C., Rossert J., et al., Predialysis Survey on Anemia Management. Predialysis Survey on Anemia Management: Patient referral. Am J Kidney Dis. 41 (2003) 49-61
3. McClellan W., Aronoff S.L., Bolton W.K., et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 20 (2004) 1501-1510
4. Perlman R.L., Finkelstein F.O., Liu L., et al. Quality of life in chronic kidney disease (CKD): A cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis. 45 (2005) 658-666
5. Foley R.N., Parfrey P.S., Kent G.M., et al. Serial change in echocardiographic parameters and cardiac failure in endstage renal disease. J Am Soc Nephrol. 11 (2000) 912-916
6. Silverberg D. Outcomes of anaemia management in renal insufficiency and cardiac disease. Nephrol Dial Transplant. 18 Suppl 2 (2003) ii7-ii12
7. Li S., Foley R.N., and Collins A.J. Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int. 65 (2004) 1864-1869
8. US Renal Data System (USRDS). 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States (2005), National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md
9. [published correction appears in Am J Kidney Dis. 1991;18:420]. US Recombinant Human Erythropoietin Predialysis Study Group. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis. 18 (1991) 50-59
10. Collins A.J. Anaemia management prior to dialysis: Cardiovascular and cost-benefit observations. Nephrol Dial Transplant. 18 Suppl 2 (2003) ii2-ii6
11. Ross S.D., Fahrbach K., Frame D., et al. The effect of anemia treatment on selected health-related quality-of-life domains: A systematic review. Clin Ther. 25 (2003) 1786-1805
12. Regidor D.L., Kopple J.D., Kovesdy C.P., et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17 (2006) 1181-1191
13. Locatelli F., Aljama P., Bárány P., et al., European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 19 Suppl 2 (2004) ii1-ii47
14. [published correction appears in Am J Kidney Dis. 2006;48:518]. KDOQI National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 47 Suppl 3 (2006) S11-S145
15. Pisoni R.L., Bragg-Gresham J.L., Young E.W., et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 44 (2004) 94-111
16. Macdougall I.C., and Eckardt K.U. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet 368 (2006) 947-953
17. Abstract 5O018. Brandt M., Lanzendörfer M., Frische J., et al. Different receptor binding activity of C.E.R.A. (continuous erythropoietin receptor activator) compared with epoetin beta determined by surface plasmon resonance and competition assay on UT-7 cells. Nephrol Dial Transplant. 21 Suppl 4 (2006) iv9
18. Abstract 592P. Dougherty F.C., Reigner B., Jordan P., and Pannier A. Continuous erythropoiesis receptor activator (C. E. R.A.) provides dose-dependent erythropoietic activity with a prolonged half-life in healthy volunteers. Ann Oncol. 15 Suppl 3 (2004) iii157
19. Abstract 89. Macdougall I.C., Reigner B., and Dougherty F.C. Consistent pharmacokinetic properties of C.E.R.A. (continuous erythro poietin receptor activator) in healthy volunteers and in patients with CRD. Am J Kidney Dis. 47 (2006) A41
20. Halstenson C.E., Macres M., Katz S.A., et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther. 50 (1991) 702-712
21. Macdougall I.C., Gray S.J., Elston O., et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 10 (1999) 2392-2395
22. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects [WMA Web site]. Adopted by the 18th WMA General Assembly. Helsinki, Finland, June 1964 (2007). http://www.wma.net/e/policy/b3.htm
23. European Agency for the Evaluation of Medicinal Products, International Conference on Harmonisation World Health Organization. Guideline for Good Clinical Practice [EMEA Web site]. ICH Topic E6. Geneva (2002-2007), WHO, Switzerland. http://www.emea.eu.int Accessed January
24. Dhondt A.W., Vanholder R.C., and Ringoir S.M. Angiotensin-converting enzyme inhibitors and higher erythropoietin requirement in chronic haemodialysis patients. Nephrol Dial Transplant. 10 (1995) 2107-2109
25. Shand B.I., Gilchrist N.L., Nicholls M.G., and Bailey R.R. Effect of losartan on haematology and haemorheology in elderly patients with essential hypertension: A pilot study. J Hum Hypertens. 9 (1995) 233-235
26. Studies BA16198, BA239, BA16346, and BA16422 (2001), F. Hoffmann-La Roche, Nutley, NJ
27. Eschbach Jr. J.W., Funk D., Adamson J., et al. Erythropoiesis in patients with renal failure undergoing chronic dialysis. N Engl J Med. 276 (1967) 653-658
28. Eschbach J.W., Haley N.R., Egrie J.C., and Adamson J.W. A comparison of the responses to recombinant human erythropoietin in normal and uremic subjects. Kidney Int. 42 (1992) 407-416
29. Available at:. US Environmental Protection Agency. Good Laboratory Practice Standards [EPA Web site]. Accessed January (2007). http://www.epa.gov/compliance/monitoring/programs/fifra/glp.html
30. Locatelli F., Canaud B., Giacardy F., et al. Treatment of anaemia in dialysis patients with unit dosing of darbe poetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant. 18 (2003) 362-369
31. Suranyi M.G., Lindberg J.S., Navarro J., et al. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am J Nephrol. 23 (2003) 106-111
32. Brunkhorst R., Bommer J., Braun J., et al., German Aranesp Study Group. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Nephrol Dial Transplant. 19 (2004) 1224-1230
33. Jadoul M., Vanrenterghem Y., Foret M., et al. Darbepoetin alfa administered once monthly maintains haemoglo bin levels in stable dialysis patients. Nephrol Dial Transplant. 19 (2004) 898-903
34. Ling B., Walczyk M., Agarwal A., et al. Darbepoetin alfa administered once monthly maintains hemoglobin con centrations in patients with chronic kidney disease. Clin Nephrol. 63 (2005) 327-334
35. Grzeszczak W., Sulowicz W., Rutkowski B., et al., European Collaborative Group. The efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin beta in peritoneal dialysis patients with chronic renal anaemia. Nephrol Dial Transplant 20 (2005) 936-944
36. Provenzano R., Bhaduri S., Singh A.K., and PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: The PROMPT study. Clin Nephrol 64 (2005) 113-123
37. de Francisco A.L., Sulowicz W., Klinger M., et al., BA16260 Study Investigators. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: A randomised, multicentre, multipledose, phase II study. Int J Clin Pract. 60 (2006) 1687-1696
38. Locatelli F., Villa G., de Francisco A.L., et al., BA16286 study investigators. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: Once monthly administration. Curr Med Res Opin. 23 (2007) 969-979
39. Provenzano R., Besarab A., Macdougall I.C., et al., BA16528 study investigators. The continuous erythropoietin receptor activator (C. E. R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: Results of a phase II study. Clin Nephrol. 67 (2007) 306-317
40. Fishbane S., and Berns J.S. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 68 (2005) 1337-1343
41. Osinski M., and Wish J. Physician workforce: Coming up short. Nephrol News Issues. 19 (2005) 58-59
42. Osinski M., and Wish J. Physician workforce: Coming up short. Nephrol News Issues. 64 (2005) 67
43. Collins A.J., Li S., Gilbertson D.T., et al. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int Suppl. 87 (2003) S24-S31
44. Alebiosu C.O., and Ayodele O.E. The global burden of chronic kidney disease and the way forward. Ethn Dis. 15 (2005) 418-423
45. Barsoum R.S. Chronic kidney disease in the developing world. N Engl J Med. 354 (2006) 997-999